Source: Eur Respir J, 55 (5) 1902370; 10.1183/13993003.02370-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Souheil El-Chemaly, Angelo Taveira-DaSilva, Shefali Bagwe, Katarzyna Klonowska, Tania Machado, Anthony M. Lamattina, Hilary J. Goldberg, Amanda M. Jones, Patricia Julien-Williams, Rie Maurer, Ivan O. Rosas, Elizabeth P. Henske, Joel Moss, David J. Kwiatkowski. Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J, 55 (5) 1902370; 10.1183/13993003.02370-2019

Member's Comments

No comment yet.

Related content which might interest you: Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study Source: Eur Respir J 2015; 46: 783-794 Year: 2015 Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial Source: Eur Respir J 2016; 47:1452-1460 Year: 2016 Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial Source: ERJ Open Res, 6 (4) 00534-2020; 10.1183/23120541.00534-2020 Year: 2020 Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013 Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002 Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis Source: Eur Respir J 2014; 43: 1114-1123 Year: 2014 Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 Placebo-controlled randomised trial of dexamethasone for quality of life in pulmonary sarcoidosis Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018